Cytek Biosciences Inc (CTKB)
Debt-to-capital ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 395,737 | 385,463 | 389,123 | 392,614 | 393,064 | 415,524 | 424,179 | 423,460 | 425,295 | 416,447 | 411,027 | 407,236 | 406,458 | 403,055 | -11,300 | -15,072 | -16,028 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $395,737K)
= 0.00
The debt-to-capital ratio for Cytek Biosciences Inc has been steadily decreasing over the years, reaching 0.00 as of December 31, 2024. This indicates that the company has effectively managed its debt relative to its capital structure. A debt-to-capital ratio of 0.00 suggests that the company has no debt or a very minimal amount of debt compared to its total capital, which can be a positive sign of financial stability and strength. It implies that the company relies more on equity financing rather than debt financing, which could potentially reduce financial risk and interest expenses. Overall, a decreasing trend in the debt-to-capital ratio reflects a healthier financial position for Cytek Biosciences Inc and may be viewed positively by investors and creditors.
Peer comparison
Dec 31, 2024